Kiniksa Pharmaceuticals International (KNSA) Enterprise Value (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Enterprise Value for 10 years, with the latest figure at -$468.1 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 23.33% year-over-year to -$468.1 million; the trailing twelve-month figure through Mar 2026 stood at -$468.1 million (down 23.33% YoY), and the FY2025 full-year result was -$414.1 million, down 69.96% from the prior year.
• Enterprise Value for Q1 2026 stood at -$468.1 million, down from -$414.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$182.1 million in Q2 2022, with the low at -$468.1 million in Q1 2026.
• Historically, Enterprise Value has averaged -$278.3 million across 5 years, with a median of -$243.6 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 35.83% — and 2024, when it sank 82.84%.
• Kiniksa Pharmaceuticals International's Enterprise Value stood at -$190.6 million in 2022, then decreased by 8.27% to -$206.4 million in 2023, then slipped by 18.05% to -$243.6 million in 2024, then tumbled by 69.96% to -$414.1 million in 2025, then slipped by 13.05% to -$468.1 million in 2026.
• The last three Enterprise Value figures came in at -$468.1 million (Q1 2026), -$414.1 million (Q4 2025), and -$352.1 million (Q3 2025), per Business Quant data.